Nurix Therapeutics (NRIX) Accounts Payables (2019 - 2025)
Historic Accounts Payables for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $11.2 million.
- Nurix Therapeutics' Accounts Payables fell 232.54% to $11.2 million in Q4 2025 from the same period last year, while for Nov 2025 it was $11.2 million, marking a year-over-year decrease of 232.54%. This contributed to the annual value of $11.2 million for FY2025, which is 232.54% down from last year.
- Nurix Therapeutics' Accounts Payables amounted to $11.2 million in Q4 2025, which was down 232.54% from $8.6 million recorded in Q3 2025.
- Nurix Therapeutics' Accounts Payables' 5-year high stood at $11.5 million during Q4 2024, with a 5-year trough of $2.2 million in Q3 2023.
- Its 5-year average for Accounts Payables is $6.0 million, with a median of $5.9 million in 2024.
- As far as peak fluctuations go, Nurix Therapeutics' Accounts Payables crashed by 6386.92% in 2023, and later skyrocketed by 11972.95% in 2025.
- Quarter analysis of 5 years shows Nurix Therapeutics' Accounts Payables stood at $6.6 million in 2021, then fell by 23.85% to $5.1 million in 2022, then increased by 26.4% to $6.4 million in 2023, then soared by 79.38% to $11.5 million in 2024, then dropped by 2.33% to $11.2 million in 2025.
- Its last three reported values are $11.2 million in Q4 2025, $8.6 million for Q3 2025, and $6.0 million during Q2 2025.